Table 2.
Emerging therapeutic targets for treatment of pruritus associated inflammatory skin diseases in humans.
| Receptors/channels | Therapeutic agents | Indications | References |
|---|---|---|---|
| TRPV1/TRPA1 | Asivatrep/PAC-14028 (TRPV1 antagonist) | Atopic dermatitis | (54, 55) |
| IL-31RA/OSMR | Nemolizumab/CIM331 (IL-31RA antagonist) | Atopic dermatitis | (83) |
| Vixarelimab/KPL-716 (OSMR antagonist) | Atopic dermatitis | (84) | |
| TSLPR | Tezepelumab/AMG-157/MEDI9929 (anti-TSLP antibody) | Atopic dermatitis | (111) |
| Topical spray containing TTLE and GA (TSLP inhibitor) | Atopic dermatitis | (113) | |
| PAR-2 | currently not available in humans | – | – |
| NK1R | Aprepitant (NK1R antagonist) | Atopic dermatitis | (168, 169) |
| Serlopitant/VPD-737 (NK1R antagonist) | Atopic dermatitis, Psoriasis | (173) | |
| Tradipitant/VLY-688 (NK1R antagonist) | Atopic dermatitis | (174) | |
| H1R/H4R | Bilastine (H1R antagonist) | Chronic spontaneous urticaria | (195) |
| Adriforant/ZPL-3893787 (H4R antagonist) | Atopic dermatitis | (193) | |
| JNJ-39758979 (H4R antagonist) | Atopic dermatitis | (202) | |
| MRGPRs | currently not available | – | – |
| TrkA | Pegcantratinib/CT327 (TrkA inhibitor) | Psoriasis | (255) |